Soliris: A Game-Changing Orphan Drug - Best Practices, LLC Case Study Reveals the Strategy Behind Its Blockbuster Success

CHAPEL HILL, N.C., Oct. 18, 2024/ -- Soliris (eculizumab), a groundbreaking treatment developed by Alexion Pharmaceuticals, has transformed the treatment landscape for two life-threatening ultra-rare disorders: paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Despite facing considerable challenges such as payer resistance due to high costs and emerging competition from biosimilars, Soliris reached blockbuster status with net sales of $2.8 billion in 2016.

Best Practices, LLC, a leading research and consulting firm, conducted an in-depth case study, "Soliris: Translating Groundbreaking Science into a Successful Orphan Drug," analyzing how Alexion’s innovative commercialization strategies, patient support programs, and extensive public relations efforts contributed to the drug’s success in the orphan drug market.

Biopharma leaders can derive actionable insights from Soliris’ journey to blockbuster success, including:

• Alexion Used a Four-Pronged Marketing Approach: Alexion’s field sales staff (32 in the U.S. and 30 in Europe) provide information to physicians and patients in regards to the diagnosis and clinical consequences of PNH. Also, regional account managers and oncology clinical specialists work with physicians to streamline practice protocols regarding the detection of PNH and aHUS. Once the physician decides to treat a patient with Soliris, the sales team works for OneSource case managers to speed the reimbursement process.

Key topics addressed in this case study:

• Soliris' first-to-market advantage and orphan drug approval
• Alexion’s global patient advocacy and support programs
• Strategic public relations campaigns that shaped public and payer perception
• The future path for Soliris amid biosimilar competition

Ready to dive deeper? Download the complimentary report summary to gain deeper insights: https://www.best-in-class.com/rw396.htm

 

Pressed for Time? Watch our video summary to learn how scientific breakthroughs, when combined with strategic patient advocacy and early market entry, can overcome payer and competitive challenges to achieve tremendous commercial success: